Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Noninvasive k3 estimation method for slow dissociation PET ligands: application to [11C]Pittsburgh compound B.

Sato K, Fukushi K, Shinotoh H, Shimada H, Hirano S, Tanaka N, Suhara T, Irie T, Ito H.

EJNMMI Res. 2013 Nov 16;3(1):76. doi: 10.1186/2191-219X-3-76.

2.

Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease.

Zhou Y, Resnick SM, Ye W, Fan H, Holt DP, Klunk WE, Mathis CA, Dannals R, Wong DF.

Neuroimage. 2007 Jun;36(2):298-312. Epub 2007 Mar 16.

3.

A short-scan method for k(3) estimation with moderately reversible PET ligands: application of irreversible model to early-phase PET data.

Sato K, Fukushi K, Shinotoh H, Shimada H, Tanaka N, Hirano S, Irie T.

Neuroimage. 2012 Feb 15;59(4):3149-58. doi: 10.1016/j.neuroimage.2011.10.087. Epub 2011 Nov 4.

PMID:
22079452
4.
5.

Reproducibility of repeated measures of deuterium substituted [11C]L-deprenyl ([11C]L-deprenyl-D2) binding in the human brain.

Logan J, Fowler JS, Volkow ND, Wang GJ, MacGregor RR, Shea C.

Nucl Med Biol. 2000 Jan;27(1):43-9.

PMID:
10755644
6.

Can target-to-pons ratio be used as a reliable method for the analysis of [11C]PIB brain scans?

Edison P, Hinz R, Ramlackhansingh A, Thomas J, Gelosa G, Archer HA, Turkheimer FE, Brooks DJ.

Neuroimage. 2012 Apr 15;60(3):1716-23. doi: 10.1016/j.neuroimage.2012.01.099. Epub 2012 Jan 27.

7.

Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.

Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, Meltzer CC, Schimmel K, Tsopelas ND, DeKosky ST, Price JC.

J Nucl Med. 2005 Dec;46(12):1959-72.

8.

Evaluation of simplified kinetic analyses for measurement of brain acetylcholinesterase activity using N-[11C]Methylpiperidin-4-yl propionate and positron emission tomography.

Sato K, Fukushi K, Shinotoh H, Nagatsuka S, Tanaka N, Aotsuka A, Ota T, Shiraishi T, Tanada S, Iyo M, Irie T.

J Cereb Blood Flow Metab. 2004 Jun;24(6):600-11.

PMID:
15181367
9.
10.
11.

Strategies for the generation of parametric images of [11C]PIB with plasma input functions considering discriminations and reproducibility.

Edison P, Brooks DJ, Turkheimer FE, Archer HA, Hinz R.

Neuroimage. 2009 Nov 1;48(2):329-38. doi: 10.1016/j.neuroimage.2009.06.079. Epub 2009 Jul 8.

PMID:
19591948
12.

Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.

Förster S, Yousefi BH, Wester HJ, Klupp E, Rominger A, Förstl H, Kurz A, Grimmer T, Drzezga A.

Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1927-36. doi: 10.1007/s00259-012-2230-9. Epub 2012 Aug 28.

PMID:
22926714
13.

Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET.

Edison P, Carter SF, Rinne JO, Gelosa G, Herholz K, Nordberg A, Brooks DJ, Hinz R.

Neuroimage. 2013 Apr 15;70:423-33. doi: 10.1016/j.neuroimage.2012.12.014. Epub 2012 Dec 20.

PMID:
23261639
14.

Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.

Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA.

J Cereb Blood Flow Metab. 2005 Nov;25(11):1528-47.

PMID:
15944649
15.

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.

Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC.

Brain. 2008 Mar;131(Pt 3):665-80. doi: 10.1093/brain/awm336. Epub 2008 Feb 7.

16.

Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tisssue input functions.

Parsey RV, Slifstein M, Hwang DR, Abi-Dargham A, Simpson N, Mawlawi O, Guo NN, Van Heertum R, Mann JJ, Laruelle M.

J Cereb Blood Flow Metab. 2000 Jul;20(7):1111-33.

PMID:
10908045
17.

Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements.

McNamee RL, Yee SH, Price JC, Klunk WE, Rosario B, Weissfeld L, Ziolko S, Berginc M, Lopresti B, Dekosky S, Mathis CA.

J Nucl Med. 2009 Mar;50(3):348-55. doi: 10.2967/jnumed.108.057612. Epub 2009 Feb 17.

18.

Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease.

Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, Ackermann U, Saunder T, Tochon-Danguy H, Jones G, Smith C, O'Keefe G, Masters CL, Rowe CC.

J Nucl Med. 2007 Apr;48(4):547-52.

19.

Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.

Carter SF, Schöll M, Almkvist O, Wall A, Engler H, Långström B, Nordberg A.

J Nucl Med. 2012 Jan;53(1):37-46. doi: 10.2967/jnumed.110.087031.

20.

Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B.

Meyer PT, Hellwig S, Amtage F, Rottenburger C, Sahm U, Reuland P, Weber WA, Hüll M.

J Nucl Med. 2011 Mar;52(3):393-400. doi: 10.2967/jnumed.110.083683. Epub 2011 Feb 14.

Supplemental Content

Support Center